Efficacy and safety comparison of DL-3-n-butylphthalide and Cerebrolysin: Effects on neurological and behavioral 
outcomes in acute ischemic stroke

Xue,Li‑Xia; Zhang,Ting; Zhao,Yu‑Wu; Geng,Zhi; Chen,Jing‑Jiong; Chen,Hao

doi:10.3892/etm.2016.3139

Efficacy and safety comparison of DL-3-n-butylphthalide and Cerebrolysin: Effects on neurological and behavioral outcomes in acute ischemic stroke

Authors:
- Li‑Xia Xue
- Ting Zhang
- Yu‑Wu Zhao
- Zhi Geng
- Jing‑Jiong Chen
- Hao Chen
View Affiliations

Affiliations: Department of Neurology, Shanghai Jiao Tong University, Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China, Department of Neurosurgery, Shanghai Jiao Tong University, Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China
Published online on: March 10, 2016 https://doi.org/10.3892/etm.2016.3139
Pages: 2015-2020

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cerebrolysin and DL-3-n-butylphthalide (NBP) have each shown neuroprotective efficacy in preclinical models of acute ischemic stroke (AIS) and passed clinical trials as therapeutic drugs for AIS. The present study was a clinical trial to assess and compare the efficacy and safety of NBP and Cerebrolysin in the reduction of neurological and behavioral disability following AIS. A randomized, double‑blind trial was conducted with enrolment of 60 patients within 12 h of AIS. In addition to routine treatment, patients were randomly assigned to receive a 10‑day intravenous administration of NBP, Cerebrolysin or placebo. National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) scores were used to evaluate the efficacy of the treatment in the patients with AIS at 11 and 21 days after the initiation of therapy. Adverse events were also analyzed among the three groups. After 10 days of treatment with NBP or Cerebrolysin, the NIHSS and BI scores at day 21 showed statistical differences compared with those in the placebo group (P<0.05). The improvements of NIHSS and BI scores in the NBP and Cerebrolysin groups were higher than those in the placebo group at days 11 and 21 (P<0.05). A statistically significant difference in the improvement of 21‑day NIHSS scores was observed between the two treatment groups (P<0.05). No significant difference was found among the three groups with regard to the rate of adverse events. Favorable outcomes and good safety were observed in the patients with moderate AIS treated with NBP or Cerebrolysin. The results indicate that NBP may be more effective than Cerebrolysin in improving short‑term outcomes following AIS. This trial is registered at ClinicalTrials.gov with clinical trial identifier number NCT02149875.

View Figures

View References

1	Chang Q and Wang XL: Effects of chiral 3-n-butylphthalide on apoptosis induced by transient focal cerebral ischemia in rats. Acta Pharmacol Sin. 24:796–804. 2003.PubMed/NCBI
2	Liu CL, Liao SJ, Zeng JS, Lin JW, Li CX, Xie LC, Shi XG and Huang RX: dl-3n-butylphthalide prevents stroke via improvement of cerebral microvessels in RHRSP. J Neurol Sci. 260:106–113. 2007. View Article : Google Scholar : PubMed/NCBI
3	Liao SJ, Lin JW, Pei Z, Liu CL, Zeng JS and Huang RX: Enhanced angiogenesis with dl-3n-butylphthalide treatment after focal cerebral ischemia in RHRSP. Brain Res. 1289:69–78. 2009. View Article : Google Scholar : PubMed/NCBI
4	Xu J, Wang Y, Li N, Xu L, Yang H and Yang Z: L-3-n-butylphthalide improves cognitive deficits in rats with chronic cerebral ischemia. Neuropharmacology. 62:2424–2429. 2012. View Article : Google Scholar : PubMed/NCBI
5	Zhang L, Yu WH, Wang YX, Wang C, Zhao F, Qi W, Chan WM, Huang Y, Wai MS, Dong J and Yew DT: DL-3-n-Butylphthalide, an anti-oxidant agent, prevents neurological deficits and cerebral injury following stroke per functional analysis, magnetic resonance imaging and histological assessment. Curr Neurovasc Res. 9:167–175. 2012. View Article : Google Scholar : PubMed/NCBI
6	Ren J, Sietsma D, Qiu S, Moessler H and Finklestein SP: Cerebrolysin enhances functional recovery following focal cerebral infarction in rats. Restor Neurol Neurosci. 25:25–31. 2007.PubMed/NCBI
7	Zhang C, Chopp M, Cui Y, Wang L, Zhang R, Zhang L, Lu M, Szalad A, Doppler E, Hitzl M and Zhang ZG: Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res. 88:3275–3281. 2010. View Article : Google Scholar : PubMed/NCBI
8	Sharma HS, Sharma A, Mössler H and Muresanu DF: Neuroprotective effects of cerebrolysin, a combination of different active fragments of neurotrophic factors and peptides on the whole body hyperthermia-induced neurotoxicity: Modulatory roles of co-morbidity factors and nanoparticle intoxication. Int Rev Neurobiol. 102:249–276. 2012. View Article : Google Scholar : PubMed/NCBI
9	Sharma HS, Menon PK, Lafuente JV, Aguilar ZP, Wang YA, Muresanu DF, Mössler H, Patnaik R and Sharma A: The role of functionalized magnetic iron oxide nanoparticles in the central nervous system injury and repair: New potentials for neuroprotection with Cerebrolysin therapy. J Nanosci Nanotechnol. 14:577–595. 2014. View Article : Google Scholar : PubMed/NCBI
10	Cui LY, Zhu YC, Gao S, Wang JM, Peng B, Ni J, Zhou LX, He J and Ma XQ: Ninety-day administration of dl-3-n-butylphthalide for acute ischemic stroke: A randomized, double-blind trial. Chin Med J (Engl). 126:3405–3410. 2013.PubMed/NCBI
11	Hong Z, Moessler H, Bornstein N, Brainin M and Heiss WD: CASTA-Investigators: A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia - CASTA. Int J Stroke. 4:406–412. 2009. View Article : Google Scholar : PubMed/NCBI
12	Heiss WD, Brainin M, Bornstein NM, Tuomilehto J and Hong Z: Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators: Cerebrolysin in patients with acute ischemic stroke in Asia: Results of a double-blind, placebo-controlled randomized trial. Stroke. 43:630–636. 2012. View Article : Google Scholar : PubMed/NCBI
13	Lang W, Stadler CH, Poljakovic Z and Fleet D: Lyse Study Group: A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke. Int J Stroke. 8:95–104. 2013. View Article : Google Scholar : PubMed/NCBI
14	Cerebrovascular Disease Working Groups, Chinese Academy of Neurology: Guidelines for the management of ischemic stroke (China 2010). Zhonghua Shen Jing Ke Za Zhi. 43:146–153. 2010.(In Chinese).
15	Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J and Marler J: Improved reliability of the NIH stroke scale using video training. NINDS TPA stroke study group. Stroke. 25:2220–2226. 1994. View Article : Google Scholar : PubMed/NCBI
16	Sulter G, Steen C and De Keyser J: Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke. 30:1538–1541. 1999. View Article : Google Scholar : PubMed/NCBI
17	Guy W: ECDEU assessment manual for psychopharmacology (revised). U.S. Department of Health, Education, and Human Welfare Publication No. (ADM) 76–338. Rockville, MD: 341–345. 1976.
18	Liu L, Wang D, Wong KS and Wang Y: Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke. 42:3651–3654. 2011. View Article : Google Scholar : PubMed/NCBI
19	Liu M, Wu B, Wang WZ, Lee LM, Zhang SH and Kong LZ: Stroke in China: Epidemiology, prevention and management strategies. Lancet Neurol. 6:456–464. 2007. View Article : Google Scholar : PubMed/NCBI
20	Tymianski M: Novel approaches to neuroprotection trials in acute ischemic stroke. Stroke. 44:2942–2950. 2013. View Article : Google Scholar : PubMed/NCBI
21	Xiong J and Feng YP: The protective effect of butylphthalide against mitochondrial injury during cerebral ischemia. Acta Pharmaceutica Sinica. 35:408–412. 2000.
22	Zhang T, Jia W and Sun X: 3-n-Butylphthalide (NBP) reduces apoptosis and enhances vascular endothelial growth factor (VEGF) up-regulation in diabetic rats. Neurol Res. 32:390–396. 2010. View Article : Google Scholar : PubMed/NCBI
23	Zhang T, Yan W, Li Q, Fu J, Liu K, Jia W, Sun X and Liu X: 3-n-Butylphthalide (NBP) attenuated neuronal autophagy and amyloid-β expression in diabetic mice subjected to brain ischemia. Neurol Res. 33:396–404. 2011. View Article : Google Scholar : PubMed/NCBI
24	Wang HM, Zhang T, Huang JK and Sun XJ: 3-N-butylphthalide (NBP) attenuates the amyloid-β-induced inflammatory responses in cultured astrocytes via the nuclear factor-κB signaling pathway. Cell Physiol Biochem. 32:235–242. 2013. View Article : Google Scholar : PubMed/NCBI